Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Gastroenterology|March 10, 2017
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing CholangitisTobias J Weismüller, Palak J Trivedi, Annika Bergquist, et al.
Nature Genetics|December 20, 2016
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel diseaseSun-Gou Ji, Brian D Juran, Sören Mucha, et al.
Gut|August 6, 2017
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitisRudi Alberts, Elisabeth M G de Vries, Elizabeth C Goode, et al.
Nature Genetics|April 23, 2013
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitisJimmy Z Liu, Johannes Roksund Hov, Trine Folseraas, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Gastroenterology|March 10, 2017
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing CholangitisTobias J Weismüller, Palak J Trivedi, Annika Bergquist, et al.
Nature Genetics|December 20, 2016
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel diseaseSun-Gou Ji, Brian D Juran, Sören Mucha, et al.
Gut|August 6, 2017
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitisRudi Alberts, Elisabeth M G de Vries, Elizabeth C Goode, et al.
Nature Genetics|April 23, 2013
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitisJimmy Z Liu, Johannes Roksund Hov, Trine Folseraas, et al.
Pageof 19